Delivery Order 75F40124D00043-75F40125F19002
- Not listed
- This is a $6,155,378.96 time and materials contract awarded by the Food and Drug Administration (FDA) to Iqvia Government Solutions Inc. for the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative #3: Health Care Data Sources for Surveillance of Biologics (BEST 3). The contract, which runs through September 29, 2025, is not set aside. Iqvia, a leading provider of healthcare data, analytics, and related services to federal agencies, will...
- The Department of Health and Human Services Food and Drug Administration awarded a $5,273,171.50 delivery order contract to Iqvia Government Solutions Inc. to conduct surveillance activities for the safety and effectiveness of biologics. This contract is part of the BEST Initiative, a larger indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle for data tools and infrastructure to support surveillance of biologics. Iqvia Government Solutions is a for-profit organization that has...
- This is a $2,442,983.29 time-and-materials contract awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Iqvia Government Solutions Inc., a for-profit provider of healthcare data, analytics, and related services to federal agencies. The contract is for the Biologics Effectiveness and Safety (BEST) Initiative, which involves blood and blood products safety surveillance. No set-aside was used. Iqvia has held several past and current IDIQ contracts with the...
- This is a delivery order awarded to Iqvia Government Solutions Inc. under the Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics indefinite delivery, indefinite quantity (IDIQ) contract with the Food and Drug Administration (FDA). The $17,498,031.84 award will provide data sources to conduct surveillance of biologics, covering tens of millions of patients from insurers, payers, and providers. The BEST Initiative IDIQ is valued at $50 million and...
- This is a $5,967,111.25 delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to IQVIA Government Solutions Inc., a provider of healthcare data, analytics, and related services to U.S. federal agencies. The contract was awarded under the FDA's BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite delivery, indefinite quantity (IDIQ) contract vehicle. The contract is for the development and...
- This federal contract award was issued by the Food and Drug Administration (FDA) to International Business Machines Corporation (IBM) to support the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative. The $8,234,421.12 delivery order contract will develop new and innovative methods for automated reporting for CBER-regulated biologics. The contract is a Time and Materials (T&M) type and does not have a set-aside designation. IBM will be...
- This is a $4,463,492.67 firm fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Iqvia Government Solutions Inc. for "DRUG UTILIZATION: HOSPITAL INPATIENT & EMERGENCY DEPT. DATA". The contract has an ultimate completion date of August 22, 2030 and was awarded on July 23, 2025. This order is part of Iqvia's broader healthcare data and analytics work for federal agencies, as the company holds several significant Indefinite Delivery Vehicle (IDV)...
- The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $2.9 million delivery order to International Business Machines Corporation (IBM) under the BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) multiple award contract. The delivery order is for IBM to conduct surveillance activities to assess the safety and effectiveness of biologics, as part of HHS FDA's BEST Initiative. Major...
- The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $13.2 million delivery order contract to International Business Machines Corporation (IBM) under the Biologics Effectiveness and Safety (BEST) Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The contract calls for IBM to provide data, tools, and infrastructure to support HHS FDA's BEST Initiative for surveillance of...
- This federal contract was awarded by the Department of Health and Human Services Food and Drug Administration to the International Business Machines Corporation (IBM) on September 24, 2019. The $5,622,942.08 time and materials contract is a delivery order under the BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics master IDIQ contract vehicle. The objective is for IBM to conduct surveillance activities to assess the safety and effectiveness of biologics. This work...
- 75F40124D00043Indefinite Delivery Contract
- 75F40124D00043-75F40125F19002Delivery Order
This is a $4,415,338.31 delivery order contract awarded by the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) to Iqvia Government Solutions Inc., a prominent for-profit healthcare data and analytics provider. The contract is for the CBER's Biologics Effectiveness and Safety (BEST) Initiative #3, which focuses on utilizing healthcare data sources for surveillance of biologics (BEST 3). The contract is a time and materials type with a period of performance through September 29, 2026. This award is not associated with any set-aside designation, indicating it was competed on a full and open basis. Iqvia Government Solutions Inc. has extensive experience providing data, analytics, and technology solutions to various federal agencies, including the FDA, Centers for Disease Control and Prevention, and Department of Defense, through prime contracts and subgrant activities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4m | 9/29/25 |